Pulmova
Generic Name
Pulmova-267 mg tablet
Manufacturer
Global Pharma Solutions Inc.
Country
USA
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| pulmova 267 mg tablet | ৳ 45.00 | ৳ 450.00 |
Description
Overview of the medicine
Pulmova 267 mg Tablet is an oral medication used for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases (PF-ILD). It works by targeting specific pathways involved in fibrosis, helping to slow disease progression and preserve lung function.
Uses & Indications
Dosage
Adults
Initial dose 267 mg once daily, gradually titrating to 267 mg twice daily based on tolerability and response. Maximum dose 267 mg three times daily.
Elderly
No specific dose adjustment required, but monitor for adverse effects.
Renal_impairment
Mild to moderate: No dose adjustment. Severe: Not recommended due to lack of data.
How to Take
Take orally with food to reduce gastrointestinal side effects. Swallow whole, do not crush or chew.
Mechanism of Action
Pulmova selectively inhibits multiple tyrosine kinases involved in pro-fibrotic signaling pathways, including fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR). This inhibition reduces the proliferation and differentiation of fibroblasts and myofibroblasts, thereby attenuating collagen deposition and fibrosis in the lungs.
Pharmacokinetics
Onset
Clinical effects typically observed within 3-6 months of consistent therapy.
Excretion
Excreted mainly through feces (approx. 80%) and urine (approx. 10-15%).
Half life
Approximately 12-18 hours, allowing for once or twice daily dosing.
Absorption
Rapidly absorbed after oral administration, peak plasma concentrations reached within 2-4 hours.
Metabolism
Primarily metabolized in the liver via cytochrome P450 (CYP3A4) enzymes.
Side Effects
Contraindications
- •Severe hepatic impairment
- •Known hypersensitivity to Pulmova or any of its excipients
- •Pregnancy and lactation (due to insufficient data and potential risks)
Drug Interactions
P-glycoprotein (P-gp) inhibitors
May increase Pulmova exposure; caution advised.
Strong CYP3A4 Inducers (e.g., Rifampicin)
May decrease Pulmova plasma concentrations, reducing efficacy.
Strong CYP3A4 Inhibitors (e.g., Ketoconazole)
May increase Pulmova plasma concentrations, requiring dose adjustment.
Storage
Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.
Overdose
In case of overdose, seek immediate medical attention. Symptomatic and supportive treatment should be initiated. There is no specific antidote.
Pregnancy & Lactation
Not recommended during pregnancy due to potential fetal harm. Women of childbearing potential should use effective contraception. Avoid breastfeeding.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from manufacturing date.
Availability
Pharmacies and hospitals worldwide
Approval Status
Approved by regulatory bodies (e.g., FDA, EMA, DGDA)
Patent Status
Under patent protection
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
